Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Sponsor: Corbus Pharmaceuticals Inc.
Terminated
Sponsor terminated open-label extension
Other terminated trials from Corbus Pharmaceuticals Inc.
- Dermatomyositis · Phase PHASE2 · Jan 2021
- Diffuse Cutaneous Systemic Sclerosis · Phase PHASE3 · Dec 2020
More terminations from Corbus Pharmaceuticals Inc.
Other Diffuse Cutaneous Systemic Sclerosis trials with similar outcome
A PHASE2 clinical study on Diffuse Cutaneous Systemic Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Corbus Pharmaceuticals Inc. and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Feb 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Corbus Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .